Bill Text: NY A10656 | 2015-2016 | General Assembly | Introduced

---

Bill Title: Directs the department of health to include information regarding the administration of overdose reversal agents on the prescription monitoring program registry.

Spectrum: Slight Partisan Bill (Democrat 7-4)

Status: (Introduced - Dead) 2016-06-10 - referred to health [A10656 Detail]

Download: New_York-2015-A10656-Introduced.html

---

                STATE OF NEW YORK
        ________________________________________________________________________
                                          10656
                   IN ASSEMBLY
                                      June 10, 2016
                                       ___________
        Introduced by COMMITTEE ON RULES -- (at request of M. of A. McDonald) --
          read once and referred to the Committee on Health
        AN  ACT  to  amend  the  public health law, in relation to directing the
          department of health to include  information  regarding  the  adminis-
          tration  of  overdose  reversal  agents on the prescription monitoring
          program registry
          The People of the State of New York, represented in Senate and  Assem-
        bly, do enact as follows:
     1    Section 1. Subdivision 9 of section 3343-a of the public health law is
     2  renumbered  subdivision  10  and a new subdivision 9 is added to read as
     3  follows:
     4    9. (a) No later than January first, two thousand eighteen, the depart-
     5  ment shall include  on  the  prescription  monitoring  program  registry
     6  information  for  each  person  to  whom  naloxone  or  another overdose
     7  reversal agent has been dispensed to assist physicians and  other  pres-
     8  cribers identify patients who have overdosed on an opioid or on heroin.
     9    (b)  Any  person, including a first responder or medical practitioner,
    10  who administers naloxone or another overdose reversal agent to a patient
    11  in the case of a suspected or confirmed overdose shall report the admin-
    12  istration of the agent to the prescription monitoring  program  registry
    13  within  seventy-two  hours  of administration. Such report shall contain
    14  the following information if available: (i) the  name  of  the  patient;
    15  (ii) the address of the patient; (iii) the date of birth of the patient;
    16  (iv)  the time and place of the administration of the agent; and (v) the
    17  identity of the person who administered the naloxone to the patient.
    18    (c) Any report made pursuant to the terms of this subdivision shall be
    19  considered to be made by the reporter in the course of his or her duties
    20  and shall be directly related to patient care.
    21    § 2. This act shall take effect immediately.
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD15575-01-6